Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 juin 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its...
27 mai 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds

Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177Lu-edotreotide (ITM-11), following positive Phase 3 resultsFlexible funding structure enables continued advancement...
13 mars 2025 06h30 HE | Source: ITM Isotope Technologies Munich SE

ITM Announces Updates to Commercial Leadership

Dr. Sebastian Marx, ITM’s chief business officer and member of the Executive Board, is stepping down effective July 20, 2025 after nearly two decades at the company Roger Estafanos, currently U.S....
06 mars 2025 04h30 HE | Source: ITM Isotope Technologies Munich SE

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a....
25 févr. 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference

Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
28 janv. 2025 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
27 oct. 2022 05h00 HE | Source: ITM Isotope Technologies Munich SE

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...